Based in Littleton, Massachusetts, Mevion Medical Systems was founded in 2004. Its mission is to create smaller, lower-cost proton therapy technology, thereby improving accessibility and advancing the treatment of cancer. The S250i system has been granted clearance for patient treatment from the Food and Drug Administration (FDA). To date, the newer, more compact Mevion S250i system has been installed at seven U.S. proton centers in Florida, Missouri, New Jersey, Ohio, Oklahoma and Washington DC. A Salt Lake City, Utah location is under construction, and several more centers are in the planning stages.
The Mevion S250i with Hyperscan and Adaptive Aperture™ delivers high quality, robust pencil beam scanning for Intensity Modulated Proton Therapy. The patented Adaptive Aperture can automatically tailor beam characteristics to match a tumor at any spot and depth. The benefits are a sharper penumbra that eliminates dose uncertainty and delivers less radiation to healthy tissues. It is ideal for treating shallow pediatric or brain tumors, where small spot sizes are difficult to achieve.
The Adaptive Aperture is a ground-breaking, low profile Multileaf Collimator (MLC) system specifically designed for pencil beam scanning. The system uses a fully automated adaptive aperture that generates layer-by-layer specific beam collimation and blocking identical to conventional proton therapy apertures.
Sharper Spot Size Collimation: 1 to 3 mm collimated spot sizes (sigma equivalent) for all energies: 0-32 cm depth.
Faster Volumetric Scanning: Scan a typical lung tumor in < 2 seconds.
Robustness Lowers Clinical Uncertainty: 10-50x faster scanning and 2-3x sharper compared with non-IMPT treatments.
Clinical optimization: Image quality and robotic precision merge for < 1 mm IGRT positioning with in-room 3D imaging.
Please click here to visit the Mevion website and learn more about this exciting company and technology.
